Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melodie Gavin

Nurse Practitioner, Psychiatric/Mental Health Fort Wayne, IN Nurse Practitioner

NPI 1053725085 CMS profile 11057518

909 E State Blvd, Fort Wayne, IN 46805

Open in the dashboard

General payments

$8,569

559 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melodie Gavin of Fort Wayne, IN is reported in the CMS Open Payments database as having received $8,569 across 559 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,473 151
2024 General $1,992 127
2023 General $1,346 88
2022 General $1,254 73
2021 General $1,504 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melodie Gavin
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Melodie Gavin were reported at $2,473. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Melodie Gavin Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,504 $166 $54–$482 $132
2022 $1,254 $195 $66–$559 $149
2023 $1,346 $233 $82–$673 $160
2024 $1,992 $236 $84–$688 $164
2025 $2,473 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,472 118 payments
  2. Lundbeck LLC $1,390 142 payments
  3. Otsuka America Pharmaceutical, Inc. $1,169 57 payments
  4. Sunovion Pharmaceuticals Inc. $642 33 payments
  5. Alkermes, Inc. $460 26 payments
  6. Neurocrine Biosciences, Inc. $453 23 payments
  7. Axsome Therapeutics, Inc. $452 14 payments
  8. ITI, Inc. $386 21 payments
  9. Vanda Pharmaceuticals Inc. $327 25 payments
  10. Indivior Inc. $300 15 payments
  11. Other $1,518 85 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,451 549 payments
  2. Education $119 10 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $979 82 payments
  2. REXULTI Psychiatry $816 41 payments
  3. REXULTI Psychiatry $782 82 payments
  4. LATUDA $642 33 payments
  5. VRAYLAR Neuroscience $493 36 payments
  6. ABILIFY MAINTENA $476 50 payments
  7. ABILIFY ASIMTUFII $463 23 payments
  8. Auvelity $435 13 payments
  9. ARISTADA Cns $432 25 payments
  10. ARISTADA Cns $432 25 payments
  11. Other $4,418 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,163

Median for Nurse Practitioner: 389

Drug cost

$333,416

Median for Nurse Practitioner: $21,885

Branded share of claims

37.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 12 $100,571
Abilify Asimtufii Aripiprazole Brand 12 $69,822
Abilify Maintena Aripiprazole Brand 22 $68,274
Rexulti Brexpiprazole Brand 25 $34,369
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 251 $26,955
Belsomra Suvorexant Brand 36 $17,776
Ramelteon Generic 17 $1,453
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 11 $1,344
Gabapentin Generic 108 $1,288
Topiramate Generic 32 $1,226

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$5,000

Medicare's payments for the services billed

Medicare patients

28

Average age 54

Services billed

113

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 61%
High blood pressure 54%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $327
  • Otsuka America Pharmaceutical, Inc. $275
$603 25 —
VRAYLAR
  • AbbVie, Inc. $379
$379 — —
ABILIFY ASIMTUFII
  • Lundbeck LLC $125
  • Otsuka America Pharmaceutical, Inc. $33
$158 12 —
Auvelity
  • Axsome Therapeutics, Inc. $141
$141 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

559 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record